Jobe A H
Harbor-UCLA Medical Center, UCLA School of Medicine, Torrance 90509.
Early Hum Dev. 1992 Jun-Jul;29(1-3):57-62. doi: 10.1016/0378-3782(92)90058-o.
Surfactant is now available for general clinical use in infants with RDS. While surfactant is effective, it does not prevent lung disease in many preterm infants because of other aspects of lung immaturity. In experimental models, corticosteroids alter the fetal lung by improving compliances, increasing lung volumes, decreasing pulmonary edema, and altering surfactant-compliance dose response curves. These effects are independent of changes in surfactant pools but augment the responses of the lungs to surfactant treatment. Optimal outcomes for the preterm require the combined use of fetal maturation strategies and postnatal surfactant.
表面活性剂现已可用于患有呼吸窘迫综合征（RDS）的婴儿的一般临床治疗。虽然表面活性剂是有效的，但由于肺部不成熟的其他方面，它并不能预防许多早产儿的肺部疾病。在实验模型中，皮质类固醇通过改善顺应性、增加肺容量、减少肺水肿以及改变表面活性剂-顺应性剂量反应曲线来改变胎儿肺。这些作用独立于表面活性剂池的变化，但增强了肺对表面活性剂治疗的反应。早产的最佳治疗效果需要胎儿成熟策略和出生后表面活性剂的联合使用。
